STOCK TITAN
  1. Home
  2. News
  3. STXS

Stereotaxis Inc - STXS STOCK NEWS

Welcome to our dedicated news page for Stereotaxis (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stereotaxis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stereotaxis's position in the market.

News
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
Rhea-AI Summary
Stereotaxis, a leader in surgical robotics for minimally invasive endovascular intervention, will report its first quarter 2024 financial results on May 13, 2024. The company will host a conference call and webcast to discuss the results and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences earnings
-
News
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
Rhea-AI Summary
Stereotaxis (NYSE: STXS) announced regulatory submissions in Europe and the US for the MAGiC™ catheter, showing promising initial clinical results. The catheter aims to enhance patient safety and procedural effectiveness in minimally invasive cardiac ablation procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.9%
Tags
none
-
News
Stereotaxis Reports 2023 Full Year Financial Results
Rhea-AI Summary
Stereotaxis (STXS) reports financial results for Q4 and full year 2023, emphasizing progress in strategic transformation. The company anticipates breakout growth in 2024 with regulatory submissions made for proprietary ablation catheter, testing of smaller robot, and upcoming commercial launches. However, revenue growth faced challenges due to product dependencies, impacting system revenue. Despite this, Stereotaxis maintains a strong balance sheet to support its product ecosystem and aims for profitability in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.9%
Tags
earnings
News
Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology
Rhea-AI Summary
Stereotaxis (STXS) announces the first treatment of patients with the Genesis Robotic Magnetic Navigation system at Intermountain Medical Center, a leading provider of robotic heart rhythm care. The Genesis RMN system offers precision and safety in treating arrhythmias, benefiting millions worldwide. Intermountain's commitment to advanced technology and patient care is evident through this new robotic heart care program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.54%
Tags
none
-
News
Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Rhea-AI Summary
Stereotaxis (STXS) to release financial results for Q4 and full year 2023 on March 4, 2024. Conference call scheduled to discuss results and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
conferences earnings
-
News
Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter
Rhea-AI Summary
Stereotaxis (STXS) announced the successful treatment of the first patients using its Magnetic Interventional Ablation Catheter, MAGiC™, designed for minimally invasive cardiac ablation procedures. The first human procedures using the MAGiC catheter were performed at Vilnius University Hospital Santaros Klinikos in Lithuania, with eight patients treated in the first week of January. Data from the clinical trial will support the CE Mark submission of MAGiC, marking a significant milestone for Stereotaxis as they advance their comprehensive innovation strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
none
News
Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients
Rhea-AI Summary
Stereotaxis (STXS) and Baptist Health Lexington announced the successful treatment of patients using the newest advancement in the technology, the Genesis Robotic Magnetic Navigation (RMN) System. This represents a significant milestone in the field of surgical robotics for minimally invasive endovascular intervention. Baptist Health Lexington has become the first in Kentucky, and one of the first in the world, to provide the latest advancement in robotic technology to treat cardiac arrhythmias.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
-
News
Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Stereotaxis (NYSE: STXS) to participate in the Piper Sandler 35th Annual Healthcare Conference. David Fischel, Chairman and CEO, will present on Stereotaxis’ business and technology during a Fireside Discussion on November 30, 2023, at 1:30 pm ET. He will also be available for one-on-one meetings. The company aims to share its differentiated technology, clinical value, and growth strategy with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
-
News
Stereotaxis Reports 2023 Third Quarter Financial Results
Rhea-AI Summary
Stereotaxis (NYSE: STXS) reports Q3 2023 financial results with $7.8 million in revenue, driven by system revenue growth and a robust innovation strategy. The company remains confident in its ability to realize its innovation strategy with current resources.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
earnings
News
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
Rhea-AI Summary
Stereotaxis successfully treats first patients in the US with the integration of Abbott's EnSite™ X EP System and Stereotaxis' Robotic Magnetic Navigation System. The procedures were completed at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center. Physicians are pleased with the progress towards open interoperability and the benefits for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none
Stock STXS logo
Stereotaxis Inc

NYSE:STXS

STXS Rankings

#3779 Ranked by Market Cap
#3509 Ranked by Stock Gains
N/A Ranked by Dividends

STXS Stock Data

222.57M
56.29M
15.87%
47.5%
1.13%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
St Louis

About STXS

stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. these innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. over 100 issued patents support the stereotaxis platform. the core components of stereotaxis’ systems have received regulatory clearance in the united states, european union, japan, canada, china, and elsewhere. for more information, please visit www.stereotaxis.com.